跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 13,040 条关于
“Garsorasib (D-1553)”
全部
13,040
临床试验
4,624
药物
1,897
机构
3,096
资讯
3,423
9个月前
Garsorasib Shows 45.5% Response Rate in KRAS G12C-Mutated Pancreatic Cancer Patients
2个月前
Ifebemtinib Plus Garsorasib Shows 82% ORR and 22-Month PFS in First-Line KRAS G12C-Mutant NSCLC
去年
Adagrasib Demonstrates Superior Efficacy Over Docetaxel in KRAS G12C-Mutated NSCLC
去年
Yifang Biopharma's TYK2 Inhibitor D-2570 Shows Promising Phase II Results in Psoriasis Treatment
去年
Sino Biopharm's Garsorasib Approved in China for Advanced NSCLC
去年
InxMed Reports Breakthrough Results for Ifebemtinib-Garsorasib Combination in KRAS G12C-Mutant Cancers at ASCO 2025
4个月前
D&D Pharmatech Raises $165M as MASH Drug DD01 Approaches Key Phase 2 Readout
去年
InxMed's Ifebemtinib Receives Breakthrough Therapy Designation for NSCLC with KRAS G12C Mutation
6个月前
D&D Pharmatech and First Bio Secure European Patent for Novel Brain Disease Drug NLY02
去年
D&D Pharmatech Completes Enrollment for Phase 2 MASH Trial of Novel Dual GLP-1/Glucagon Agonist DD01
第 1 页,共 343 页
上一页
下一页